论文部分内容阅读
目的探讨MRP1、ToPo-Ⅱ在非小细胞肺癌(NSCLC)中的表达及其临床意义。方法采用免疫组织化学法检测117例NSCLC,26例对照组断端支气管黏膜中MRP1、ToPo-Ⅱ的表达水平。结果 (1)MRP1在NSCLC阳性表达高于对照组(P<0.05),与组织类型、分期、淋巴结转移有关(P<0.05);MRP1在鳞癌中的表达低于腺癌(P<0.05);随分期增高,淋巴结转移表达增强;MRP1表达与性别、年龄、分化无关(P>0.05)。(2)ToPo-Ⅱ表达在NSCLC组高于对照组(P<0.05);与组织类型、分化有关(P<0.05);鳞癌ToPo-Ⅱ表达高于腺癌;随分化程度降低表达增强(P<0.05);ToPo-Ⅱ与性别、年龄、分期、淋巴结转移无关(P>0.05)。(3)MRP1与ToPo-Ⅱ呈负相关(r=-0.269,P<0.05)。结论 NSCLC存在MRP1及ToPo-Ⅱ的高表达,两者可能参与肿瘤进展。
Objective To investigate the expression and clinical significance of MRP1 and ToPo-Ⅱ in non-small cell lung cancer (NSCLC). Methods The expression of MRP1 and ToPo-Ⅱ in bronchial mucosa of 117 cases of NSCLC and 26 cases of control group were detected by immunohistochemistry. Results (1) The positive expression of MRP1 in NSCLC was significantly higher than that in the control group (P <0.05), which was related to the histological type, stage and lymph node metastasis (P <0.05); MRP1 expression in squamous cell carcinoma was lower than that in adenocarcinoma (P <0.05) The expression of MRP1 was not correlated with gender, age and differentiation (P> 0.05). (2) The expression of ToPo-Ⅱ in NSCLC group was higher than that in control group (P <0.05), but the expression of ToPo-Ⅱ was higher in adenocarcinoma than that in control group (P <0.05) P <0.05). ToPo-Ⅱ was not related to gender, age, stage and lymph node metastasis (P> 0.05). (3) MRP1 was negatively correlated with ToPo-Ⅱ (r = -0.269, P <0.05). Conclusion There is a high expression of MRP1 and ToPo-Ⅱ in NSCLC, both of which may be involved in tumor progression.